Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPIRE-AF perioperative atrial fibrillation anticoagulation trial
NL-OMON57747Phase 4Recruiting
- Sponsor
- Population Health Research Institute
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of edoxaban, apixaban, dabigatran and rivaroxaban in Atrial fibrillation (AFib) and stroke (2 arms), sponsored by Population Health Research Institute. Primary endpoints: Non-hemorrhagic stroke and systemic embolism and Major vascular composite outcome. Started Feb 2023; status: recruiting.
02
Drugs
edoxabanapixabandabigatranrivaroxaban
03
Conditions
Atrial fibrillation (AFib)stroke
Beyond the preview
Go deeper on NL-OMON57747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57747.